Neuronetics (NASDAQ:STIM) Director Sells $62,027.26 in Stock

Key Points

• Director Keith Sullivan sold 46,289 shares on March 19 at an average of $1.34 for a total of $62,027.26, trimming his position by 2.83% but still holding 1,590,924 shares (≈$2.13M).
• Neuronetics reported quarterly revenue of $41.78M and EPS of ($0.10) (beating estimates), yet remains unprofitable with a negative ROE (121.26%) and net margin (-26.15%); market cap is about $100.8M and the stock trades near $1.46.
• Sentiment is mixed: analysts have cut targets and issued downgrades (Canaccord trimmed its PT to $3), even as major shareholder Jorey Chernett has been buying heavily, signaling conflicting insider and analyst views.

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) Director Keith Sullivan sold 46,289 shares of the firm's stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $1.34, for a total transaction of $62,027.26. Following the completion of the transaction, the director directly owned 1,590,924 shares in the company, valued at approximately $2,131,838.16. The trade was a 2.83% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Neuronetics Stock Performance

Shares of STIM opened at $1.46 on Wednesday. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.87 and a current ratio of 2.02. The stock has a 50 day moving average price of $1.58 and a two-hundred day moving average price of $1.98. The firm has a market capitalization of $100.80 million, a P/E ratio of -2.47 and a beta of 0.87. Neuronetics, Inc. has a 52 week low of $0.80 and a 52 week high of $4.97.

Neuronetics (NASDAQ:STIM - Get Free Report) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%.The firm had revenue of $41.78 million during the quarter, compared to the consensus estimate of $40.84 million. Equities analysts forecast that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on STIM shares. Wall Street Zen downgraded shares of Neuronetics from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings reiterated a "sell (e+)" rating on shares of Neuronetics in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group dropped their price target on shares of Neuronetics from $7.00 to $3.00 and set a "buy" rating on the stock in a research report on Thursday, March 19th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $3.00.

Institutional Trading of Neuronetics

Hedge funds have recently bought and sold shares of the business. Presidio Capital Management LLC purchased a new position in Neuronetics in the third quarter worth $32,000. Intrua Financial LLC bought a new position in Neuronetics in the 3rd quarter valued at $33,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of Neuronetics during the 3rd quarter valued at $33,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Neuronetics during the 2nd quarter valued at $34,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Neuronetics during the 2nd quarter worth $37,000. 53.59% of the stock is currently owned by institutional investors.

Trending Headlines about Neuronetics

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Company reported higher revenue, narrowed loss and set a 2026 outlook — this operational improvement and guidance can support valuation uplift. Neuronetics reports higher revenue, narrows loss, sets 2026 outlook
• Positive Sentiment: Major shareholder Jorey Chernett has been buying heavily (recent purchases total hundreds of thousands of shares across several days), signaling insider conviction and providing buying support. Neuronetics NASDAQ: STIM Major Shareholder Jorey Chernett Buys 169,472 Shares
• Neutral Sentiment: Board/management change — Dan Reuvers was appointed CEO, succeeding Keith Sullivan. Leadership changes introduce execution risk but may be neutral if transition is smooth. Neuronetics appoints Dan Reuvers as CEO, succeeding Keith Sullivan
• Neutral Sentiment: Analyses remain mixed — a Seeking Alpha piece calls STIM highly speculative but highlights revenue growth as a potential catalyst; this keeps sentiment bifurcated. Neuronetics: Highly Speculative, But Revenue Growth Could Drive The Stock Higher
• Neutral Sentiment: Short‑interest data released appears to contain errors (zero/NaN values), so no clear short‑pressure signal from official releases at this time.
• Negative Sentiment: Insider selling by executives and a director: EVP William Andrew Macan, EVP Steven Pfanstiel and Director Keith J. Sullivan sold shares on March 19th — such sales can be viewed negatively by the market even though insiders still retain large positions. SEC insider sale filings
• Negative Sentiment: Analyst moves and price‑target cuts: Canaccord trimmed its PT from $7 to $3 (still a buy), while other firms lowered ratings or maintained sell views — downward revisions and mixed analyst sentiment are pressuring the stock. MarketBeat STIM coverage (analyst updates)

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company's flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.